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Abstract
Purpose—To assess cancers diagnosed and the stage of cancer at the time of diagnosis among 
low-income, underinsured, or uninsured women who received services through the National 
Breast and Cervical Cancer Early Detection Program (NBCCEDP).
Methods—Using the NBCCEDP database, we examined the number and percent of women 
diagnosed during 2009–2011 with in situ breast cancer, invasive breast cancer, and invasive 
cervical cancer by demographic and clinical characteristics, including age, race and ethnicity, test 
indication (screening or diagnostic), symptoms (for breast cancer), and screening history (for 
cervical cancer). We examined these characteristics by stage at diagnosis, a new variable included 
in the database obtained by linking with state-based central cancer registries.
Results—There were 11,569 women diagnosed with invasive breast cancer, 1,988 with in situ 
breast cancer, and 583 with invasive cervical cancer through the NBCCEDP. Women who 
reported breast symptoms or who had diagnostic mammography were more likely to be diagnosed 
with breast cancer, and at a later stage, than those who did not have symptoms or who had 
screening mammography. Women who had been rarely or never screened for cervical cancer were 
more likely to be diagnosed with cervical cancer, and at a later stage, than women who received 
regular screenings.
Conclusions—Women served through the NBCCEDP who have not had prior screening or who 
have symptoms were more often diagnosed with late-stage disease.
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Introduction
Stage of cancer at the time of diagnosis represents one of the most important predictors of 
cancer morbidity and long-term survival [1]. Cancer stage represents the extent of the cancer 
and is used along with other tumor characteristics to help determine what type of treatment 
is needed [2]. To stage cancer, doctors look at the size of the tumor and whether it has 
spread to other areas in the body. They use a systematic measurement known as the tumor 
nodes metastasis (TNM) system which was developed in the late 1940s [3, 4]. This system 
has three basic components: (1) size of primary tumor (T), (2) involvement in local and 
regional lymph nodes (N), and (3) whether the cancer has spread to distant organs, also 
called metastasis (M).
Population-based data on cancer stage are collected through cancer registries such as the 
National Program for Cancer Registries administered through the Centers for Disease 
Control and Prevention (CDC) [5] and the Surveillance, Epidemiology, and End Result 
(SEER) Program administered through the National Cancer Institute [6]. These data provide 
critically important information used for monitoring cancer rates and trends, planning cancer 
control and prevention efforts, and evaluating screening programs. Healthy People 2020 
objectives monitor specific outcomes regarding reducing invasive cervical cancer incidence 
rates to 7.1 per 100,000 women and late-stage female breast cancer rates to 41.0 per 100,000 
women [7]. A recent study using cancer registry data representing 97 % of the US 
population found that these targets were not met; in 2010, the invasive cervical cancer rate 
was 7.5 per 100,000 women and the late-stage female breast cancer rate was 41.7 per 
100,000 women [8].
Screening is one way to find female breast and cervical cancers at earlier stages when 
treatment is most effective and to identify precancerous changes of the cells before they 
become malignant [9–12]. In response to the burden of breast and cervical cancer, the CDC 
was authorized by Congress to establish the National Breast and Cervical Cancer Early 
Detection Program (NBCCEDP) in 1990 to provide breast and cervical cancer screening and 
diagnostic services to low-income, under- and uninsured women who would otherwise have 
no access to these services. Details on the implementation of the NBCCEDP have been 
published elsewhere [13]. The NBCCEDP specifically aims to provide services to women 
who are not getting routine screening. From 1991 to 2012, NBCCEDP grantees served more 
than 4.5 million women and diagnosed more than 65,000 breast and cervical cancers and 
160,000 premalignant cervical lesions [14].
Research has shown that 5-year survival is much higher when cancer is diagnosed at an 
early stage than at a distant stage [15]. The relative 5-year survival for breast cancer is 99 % 
when diagnosed at a local stage, compared with 25 % when diagnosed at a distant stage; 
similarly, the relative 5-year survival for cervical cancer is 91 % when diagnosed at a local 
stage and 16 % at a distant stage. A previous report on the stage of diagnosis among women 
diagnosed with cancer through the NBCCEDP from 1991 to 2002 found that 74 % of breast 
cancers and 53 % of cervical cancers were found at early stage [16]. At that time, the stage 
of disease was not standardized to a single classification system and was primarily based on 
the clinical presentation at the time of initial tissue diagnosis and not on the final stage after 
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surgery and additional tests. In 2009, the NBCCEDP began linking cancer cases diagnosed 
in the program with data from state-based central cancer registries in order to obtain 
registry-standardized cancer stage information. This paper is the first description of the stage 
of cancer at the time of diagnosis using the NBCCEDP linked registry data among women 
diagnosed through funded grantees across the United States.
Methods
Data source
The NBCCEDP collects a standardized set of data elements for all breast and cervical cancer 
screening and diagnostic services provided by the grantees, known as minimum data 
elements (MDEs). The dataset contains variables on each clinical encounter including date 
of service, patient age, race, ethnicity, screening history, symptoms, indication for test, 
examination received, examination results, and final diagnosis. Demographics include age, 
race, and ethnicity. Age was categorized into groups of 40–49, 50–59, 60–64, and 65 or 
older for breast cancer and 18–29, 30–49, and 50 or older for cervical cancer. Race and 
ethnicity was categorized as white non-Hispanic, black non-Hispanic, other non-Hispanic 
(which included American Indian/ Alaska Native (AI/AN), Asian–Pacific Islander (API), 
and multiracial due to small sample sizes), Hispanic, and unknown race/ethnicity. Indication 
for test was categorized as screening or diagnostic, based on the reported indication for the 
initial mammogram or Papanicolaou (Pap) test just prior to the diagnosis, symptoms, or a 
previous abnormal examination. Screening indication included routine examination among 
women who did not present with symptoms, whereas diagnostic indication included women 
with symptoms or previous abnormal examinations. Symptoms reported were included as a 
separate category because frequently the clinical examination and report of symptoms were 
obtained after the screening test had been completed.
To supplement information on cancers detected, the NBCCEDP also collects registry-
standardized data through routine data linkages with state-based central cancer registries. 
Grantees linked data for women diagnosed from 2004 through 2011, the most recent year of 
complete registry data available. Stage at diagnosis was based on the SEER Summary Stage 
2000 which characterizes cancers as localized, regional, distant, or unknown stage as this is 
the data consistently available from all the central cancer registries through the data linkage 
[3].
Study population
The NBCCEDP population consists of low-income woman at or below 250 % of the federal 
poverty level who do not have health-care coverage for breast and cervical cancer screening 
services. Of those undergoing breast cancer screening, 48 % are non-Hispanic white women, 
followed by 25 % Hispanic women, and over half are aged 50–59 years old. Among those 
receiving cervical cancer screening, 50 % are non-Hispanic white women, followed by 23 % 
Hispanic women, and majority are between the ages of 40 and 59 years old (68 %) [17].
This analysis was restricted to years from 2009 through 2011 due to the availability of MDE 
data on indication for service (whose collection started in 2009) and availability of stage 
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data acquired through registry linkages through 2011. The study population consisted of 
17,340 women who were diagnosed with breast or cervical cancer through the NBCCEDP 
from 1 January 2009 through 31 December 2011. There were 3,200 women excluded from 
this analysis because of the following reasons: missing registry data in the MDE (2,794), 
primary cancer site was not breast or cervical (70), cancer was classified as lymphoma (4), 
discrepancy between invasive and carcinoma in situ classification (136), or a previous 
diagnosis of breast or cervical cancer (196). Although data were excluded from 3,200 
women, these women were not characteristically different from the study population. 
Missing registry data were uniform across several states that had not completed their data 
linkage with cancer registries. Cervical carcinoma in situ was not included in this study 
because it is not collected in cancer registries. After all exclusions, our final study 
population consisted of 11,569 women diagnosed with invasive breast cancer, 1,988 with 
breast carcinoma in situ, and 583 with invasive cervical cancer.
Data analysis
The number of women diagnosed with breast carcinoma in situ, invasive breast cancer, and 
invasive cervical cancer was calculated by age group, race and ethnicity, indication for test 
(screening or diagnostic), symptoms (for breast cancer), and screening history (for cervical 
cancer). The proportion of local, regional, and distant stage invasive breast and cervical 
cancer were also calculated by patient characteristics. Due to small cell sizes, we tested that 
patient characteristics were significant for differences in stage using the Monte Carlo 
simulation exact p values with significance at p value < 0.01. Using logistic regression 
modeling, adjusted odds ratios (aORs) and corresponding 95 % confidence intervals (CIs) 
for each characteristic were estimated for women diagnosed with cancer. Models were 
adjusted for age, race/ethnicity, indication for test, breast symptoms (breast cancer analysis 
only), and screening history (cervical cancer analysis only). All analyses were performed 
using SAS software version 9.2 (SAS Institute, Cary, North Carolina).
Results
During 2009–2011, 1,988 women were diagnosed with breast carcinoma in situ through the 
NBCCEDP (Table 1). Although the odds of being diagnosed with breast carcinoma in situ 
were higher among women aged 50–64 years, about half of cases were among women aged 
50–59 years, and half were among non-Hispanic white women. One-third of the women 
diagnosed with carcinoma in situ were reportedly being tested for diagnostic reasons, and 64 
% reported breast symptoms.
During the study period, 11,569 women were diagnosed with invasive breast cancer through 
the NBCCEDP (Table 2). Similar to breast carcinoma in situ, about half of the women 
diagnosed with invasive breast cancer were aged 50–59 years and the odds of having breast 
cancer were higher for older women. While 60 % of the women with invasive breast cancer 
were non-Hispanic white women, the odds of having invasive breast cancer were the same 
among non-Hispanic white and black women, but lower among “other” non-Hispanic 
women (i.e., AI/AN, API, and multiracial women) and Hispanic women. Approximately 62 
% of the women with invasive breast cancer were tested for a diagnostic indication. While 
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only one-third reported breast symptoms, these women had much higher odds of being 
diagnosed with invasive breast cancer than those who did not report symptoms. By stage at 
the time of breast cancer diagnosis, 48 % had local disease, 39 % had regional disease, and 
only 7 % had distant disease (Table 3). Age at diagnosis, race/ethnicity, and indication for 
test was independently associated with stage at the time of breast cancer diagnosis (p value < 
0.0001). Women 40–59 years had a higher proportion of regional stage breast cancer 
compared to women 60 years or older. Regional and distant stage breast cancer was more 
common among non-Hispanic black women than among women of other racial/ethnic 
groups. By test indication, 61 % of women with screening indication more often presented 
with local breast cancer compared to 42 % of women who had a diagnostic indication. 
Similarly, 62 % of women who did not report breast symptoms presented with local disease 
compared to 41 % of women who did.
During 2009–2011, 583 women were diagnosed with invasive cervical cancer through the 
NBCCEDP (Table 4). Very few women (4 %) diagnosed with invasive cervical cancer were 
under the age of 30 years. “Other” non-Hispanic women and Hispanic women had lower 
odds of being diagnosed with invasive cervical cancer. Most women (64 %) with invasive 
cervical cancer were tested for a screening indication, but women who were tested for a 
diagnostic indication had higher odds of cervical cancer. Women who had rarely or never 
been screened for cervical cancer had higher odds of cervical cancer than those who were 
screened within the past 5 years. By stage at the time of cervical cancer diagnosis, 36 % had 
local disease, 41 % had regional disease, and 12 % had distant disease (Table 5). Stage at the 
time of cervical cancer diagnosis did not statistically differ by age, race/ethnicity groups, 
screening history, and test indication.
Discussion
This paper describes the first report of the new cancer registry data elements in the 
NBCCEDP database collected from linkages with state-based central cancer registries. This 
provides a more standardized description of cancer stage than the previous process where 
data were based on initial cancer detection rather than final staging procedures.
This study finds that slightly less than half of women diagnosed with invasive breast cancer 
in the NBCCEDP were diagnosed at an early stage and more than one-third at a regional 
stage. During 2004–2006, 62 % of women aged 50 years or older in the United States were 
diagnosed with breast cancer at an early stage and 28 % at a regional stage [18]. Compared 
to the general population, Wu et al. [19] showed that women enrolled in the NBCCEDP 
were more likely to have later stage breast disease than matched women not enrolled in the 
NBCCEDP. This is consistent with the fact that women served in the NBCCEDP may not 
receive regular mammograms and present with symptoms, indicating breast cancer is 
already present.
Our study found that more than half of women diagnosed with cervical cancer in the 
NBCCEDP had late-stage (regional or distant) disease. During 2004–2006, 36 % of women 
in the United States were diagnosed with cervical cancer at regional stage [18]. Similar to 
breast cancer, a higher proportion of women in the NBCCEDP present with regional disease 
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at the time of diagnosis than in the general population. This may not be surprising as the 
NBCCEDP focuses efforts for cervical cancer screening on women who have never been 
screened or who have not been screened within the previous 5 years. These women are more 
likely to present with late-stage disease [20]. Studies have shown that 60 % of women 
diagnosed with invasive cervical cancer have never been screened or not screened in the past 
5 years [21].
Our findings are subject to several limitations. First, registry data elements were missing for 
15 % of women with breast cancer and 30 % of women with cervical cancer. Therefore, 
these cases were not included in the analysis. Second, the stage of cancer at the time of 
diagnosis was unknown for approximately 6 % of breast cancer cases and 12 % of cervical 
cancer cases; however, this is consistent with other studies using registry data [18]. Third, 
the indication for test may have been misclassified in some cases; for example, some women 
were recorded as receiving a screening (not diagnostic) mammogram, but their records 
showed that they had an abnormal clinical breast examination prior to the mammogram or 
that the woman reported breast symptoms. Fourth, screening history for cervical cancer 
cases was self-reported and was not verified through medical records review. Last, because 
the NBCCEDP serves a very small percentage of the eligible population [22, 23], the 
findings of this evaluation cannot be generalized to all low-income women in the United 
States.
Even though the goal of cancer screening is to find cancer in early stages with the highest 
survival rates or to prevent cancer, many women served through the NBCCEDP were 
diagnosed at later stages. This is not surprising since the NBCCEDP only serves low-income 
women who do not have access to screening services or routine health care. Many of these 
women served actually required diagnostic services rather than true screening services. 
Others have reported that women who are symptomatic have been found to have later stage 
disease [24]. Also the women served through the NBCCEDP typically do not get routine 
preventive health care or have a primary source of health care which may be related to the 
missed opportunity at finding breast cancer early or preventing development of invasive 
cervical cancer [25]. For many women, the NBCCEDP provides the only source of access 
for breast and cervical cancer detection and treatment services [13].
While the NBCCEDP has served millions of women, more work is needed in states to 
identify, educate, provide community outreach services through community health workers 
and patient navigation, and provide appropriate screening services to women who are at the 
highest risk for developing breast and cervical cancer. Continued assessment of the women 
diagnosed with cancer within and outside of the NBCCEDP can help the program improve 
its targeted efforts and work with other organizations such as employers, health insurers, and 
health-care systems to improve screening, diagnostic, and treatment services among all 
women in the United States [17]. These efforts are important factors in working toward the 
Healthy People 2020 goals of reducing female breast cancer death rates (C-3), reducing 
cervical cancer death rates (C-4), reducing invasive cervical cancer (C-10), and reducing 
late-stage female breast cancer (C-11) [7].
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Table 1
Characteristics and adjusted odds ratiosa of women diagnosed with breast carcinoma in situ through the 
National Breast and Cervical Cancer Early Detection Program, 2009–2011
Characteristics n (%) OR (95 % CI)
Overall 1,988 (100.0) N/A
Age group
 40–49 years 616 (31.0) Referent
 50–59 years 946 (47.6) 1.24 (1.12–1.38)
 60–64 years 394 (19.8) 1.42 (1.25–1.61)
 ≥65 years 32 (1.6) 1.45 (1.00–2.05)
Race/ethnicity
 White, non-Hispanic 1,078 (54.2) Referent
 Black, non-Hispanic 385 (19.4) 0.99 (0.88–1.12)
 Hispanic 341 (17.2) 0.62 (0.55–0.70)
 Other, non-Hispanic 152 (7.6) 0.79 (0.66–0.93)
 Unknown 32 (1.6) 0.76 (0.52–1.07)
Indication for test
 Screening 1,229 (61.8) Referent
 Diagnostic 660 (33.2) 1.31 (1.18–1.45)
 Unknown 99 (5.0) 2.76 (2.23–3.38)
Breast symptoms
 No 486 (24.4) Referent
 Yes 1,271 (63.9) 3.04 (2.71–3.40)
 Unknown 231 (11.6) 1.94 (1.68–2.23)
aAdjusted for age, race/ ethnicity, indication for test, and breast symptoms
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Table 2
Characteristics and adjusted odds ratiosa of women diagnosed with invasive breast cancer through the 
National Breast and Cervical Cancer Early Detection Program, 2009–2011
Characteristics n (%) OR (95 % CI)
Overall 11,569 (100.0) N/A
Age group
 40–49 years 3,403 (29.4) Referent
 50–59 years 5,408 (46.7) 1.75 (1.67–1.83)
 60–64 years 2,587 (22.4) 2.59 (2.45–2.73)
 ≥65 years 171 (1.5) 2.44 (2.07–2.85)
Race/ethnicity
 White, non-Hispanic 6,912 (59.7) Referent
 Black, non-Hispanic 2,168 (18.7) 0.95 (0.91–1.00)
 Hispanic 1,552 (13.4) 0.48 (0.45–0.51)
 Other, non-Hispanic 701 (6.1) 0.72 (0.67–0.78)
 Unknown 236 (2.0) 0.96 (0.83–1.09)
Indication for test
 Screening 3,889 (33.6) Referent
 Diagnostic 7,224 (62.4) 3.07 (2.94–3.20)
 Unknown 456 (3.9) 3.73 (3.36–4.12)
Breast symptoms
 No 6,803 (58.8) Referent
 Yes 3,775 (32.6) 11.25 (10.76–11.77)
 Unknown 991 (8.6) 2.61 (2.43–2.80)
aAdjusted for age, race/ ethnicity, indication for test, and breast symptoms
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Table 4
Characteristics and adjusted odds ratiosa of women diagnosed with invasive cervical cancer through the 
National Breast and Cervical Cancer Early Detection Program, 2009–2011
Characteristics n (%) OR (95 % CI)
Overall 583 (100.0) N/A
Age group
 18–29 years 23 (3.9) Referent
 30–49 years 295 (50.6) 7.78 (5.13–12.37)
 ≥50 years 265 (45.5) 7.71 (5.02–12.41)
Race/ethnicity
 White, non-Hispanic 334 (57.3) Referent
 Black, non-Hispanic 78 (13.4) 0.83 (0.64–1.05)
 Hispanic 124 (21.3) 0.58 (0.47–0.72)
 Other, non-Hispanic 37 (6.3) 0.53 (0.37–0.73)
 Unknown 10 (1.7) 0.68 (0.34–1.23)
Indication for test
 Screening 375 (64.3) Referent
 Diagnostic 184 (31.6) 13.59 (11.19–16.46)
 Unknown 24 (4.1) 2.47 (1.58–3.67)
Screening history
 Screened within past 5 years 242 (41.5) Referent
 Rarely/never screened 221 (37.9) 3.59 (2.97–4.32)
 Unknown 120 (20.6) 3.92 (3.13–4.89)
aAdjusted for age, race/ ethnicity, indication for test, and screening history
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